Best Biopharma Outsourcing Companies in United Kingdom
The 520 best Biopharma Outsourcing companies in United Kingdom in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Almac Group.
Ranked by disclosed equity funding and recent funding momentum, this directory covers 520 Biopharma Outsourcing companies based in the United Kingdom, and the numbers behind them are worth sitting with. The global market stood at $28.7B in 2024 and is forecast to reach $112.3B by 2032, a CAGR of 5.8% driven by surging biologics demand and rising drug development costs. That's a lot of contract revenue flowing toward firms that can clear the bar on regulatory compliance, which is tightening on both sides of the Atlantic.
So what does the UK slice look like? Total disclosed funding across these 520 companies hits $1.9B, with no unicorns yet but some genuinely outsized bets. Oxford Biomedica leads at $150M raised, which is a different order of magnitude from the next tier: Abingdon Health at $24M, Biofortuna at $22M, Lindus Health at $23M, Seda at $20M. I'd call that a pronounced funding cliff between the front-runner and the pack. Clinical trial outsourcing is the hottest theme in coverage right now, and if you're scanning for momentum, median install growth across outsourcing-adjacent apps is running at roughly 13% year-on-year. The most active backers here include Mercia, Northern Powerhouse Investment Fund, and BioCity, regional investors who are clearly not waiting for London to notice.
- ResearchAndMarkets.com
Our analysis of 100 Biopharma Outsourcing companies
$10.3b in tracked funding; 68% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Biopharma Outsourcing companies in United Kingdom
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Tech stack | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Almac Group CRAMS company offering preclinical development and CDMO services, also offering companion diagnostic… | $339M | 45 mo ago | 2,109 2,109 → 4,895 (+132%) · sector median +45% | 2001 | Alan Armstrong CEO & Chairman | WordPress Block EditorWordPressApple iCloud Mail+35 | 10 signals ▲400% Capital raise · Announcements · New product | — | 1 award |
| 2 | Clinigen Services in clinical trials & medicine supply | $167M | 132 mo ago | 1,200 | 2010 | Jerome Charton CEO | SalesforceMicrosoft ASP.NETAmazon Web Services+22 | — | 5 patents Anticancer agents: purine topoisomerase II inhibitors and amifostine-based chemoprotection. | — |
| 3 | Oxford BioMedica Manufacturer of viral vectors for cell and gene therapy products | $150M | 10 mo ago | 815 815 → 933 (+14%) · sector median +45% | 1995 | Neill Mackenzie Founder | WordPressSentryMySQL+27 | 12 signals Earnings · Funding · Announcements | 427 patents Lentiviral vector design, production, and purification for gene‑therapy applications | — |
| 4 | Ascend Provider of drug research & development and clinical trial services for cell & gene therapeutic services | $132M | 39 mo ago | 92 | 2021 | — | — | — | — | — |
| 5 | Vernalis Drugs for the treatment of cough, asthma, migraine and cancer. | $132M | 121 mo ago | 85 | 1999 | — | WordPressApple iCloud MailMicrosoft 365+16 | — | 1,306 patents Small-molecule oncology drugs targeting apoptosis regulators and kinases (Bcl‑xL, Mcl‑1, LRRK2). | — |
| 6 | Abzena Provider of antibody discovery, cell line development, and bio analytics services | $69M | 50 mo ago | 306 306 → 444 (+45%) · sector median +45% | 2001 | Jonathan Goldman CEO | WordPressApple iCloud MailMicrosoft 365+34 | 5 signals ▲150% Leadership | 9 patents Therapeutic antibody-drug conjugates targeting PSMA for cancer treatment | — |
| 7 | Quotient Bioresearch CRO providing early stage drug development services and consulting | $62M | 213 mo ago | 200 | 1992 | — | — | — | 2 patents Biomolecule recovery processes for biopharmaceutical manufacturing | — |
| 8 | eXmoor Provider of cell & gene therapautic services for biopharmaceutical sector | $52M | 36 mo ago | 80 | 2004 | — | WordPressApple iCloud MailMySQL+19 | — | — | — |
| 9 | Alliance International consumer healthcare business managing brands and partnerships | $45M | 96 mo ago | 249 249 → 521 (+109%) · sector median +45% | 1998 | Peter Butterfield CEO | AzureCloudflarejQuery+7 | — | 15 patents Food processing (chocolate formulation) and financial trading/liquidity management software platforms. | — |
| 10 | Fine Industries Contract manufacturer of high-quality fine chemicals for use in the Crop Protection, Pharmaceutical and… | $41M | 151 mo ago | 220 | 1977 | — | — | — | — | — |
| 11 | Ennogen Pharmaceutical and medical device company manufacturing API | $37M | 25 mo ago | — | 2011 | John Ruprai Founder & CEO | WordPressMySQLPHP+9 | — | — | — |
| 12 | Diaceutics Analytics based integrator for precision medicine | $31M | 72 mo ago | 151 | 2005 | — | Apple iCloud MailMicrosoft 365Ruby+15 | 5 signals ▼64% Earnings · Leadership | — | 1 partnership |
| 13 | hVIVO Provider of clinical development, laboratory, and human challenge trial services | $31M | 93 mo ago | 133 | 1998 | John Oxford Founder | WordPressApple iCloud MailMySQL+25 | — | 18 patents Therapeutic compounds targeting cytokine storm and severe influenza, e.g., MAPK inhibitors | — |
| 14 | Chemoxy Contract manufacturer of intermediates | $31M | 135 mo ago | 150 | 1868 | — | — | — | — | 1 launch |
| 15 | MIP Discovery Provider of nanoparticle design, development & manufacturing services | $31M | 27 mo ago | 32 | 2015 | Stephane Argivier CEO | — | — | 3 patents Patents concentrated in computing, sensing & instrumentation | — |
| 16 | Mosaic Therapeutics Developer of targeted cancer combination therapies | $28M | 38 mo ago | 21 | 2020 | Mathew Garnett Co-Founder | WordPressMySQLPHP+17 | — | — | — |
| 17 | Letoon Holding Biotech company producing medicinal oil | $25M | 31 mo ago | — | 2023 | Giuseppe Perla Co-Founder | — | — | — | — |
| 18 | Abingdon Health Developer of immunoassays for diagnostic purposes 57Funding top 29%Growth top 33%Market top 46%Moat top 48% All 7 signals ▾Fundingtop 29% Growthtop 33% Markettop 46% Moattop 48% Techbottom 49% Newsbottom 40% Globalbottom 32% Funding: Raised $24.1M across 8 rounds · 8 rounds over 14 yrs (0.6/yr) Growth: Headcount 51 → 151 (+196%) across vintages · 2 acquisition/expansion moves in 24 mo rank vs industry peers · Fliar Intelligence Index 57/100 | $24M | 8 mo ago | 151 151 → 91 (-40%) · sector median +45% | 2008 | — | WordPressMySQLPHP+19 | 3 signals ▼67% Earnings | — | 2 awards |
| 19 | Lindus Health Provider of contract based clinical trial & recruitment services | $23M | 16 mo ago | 7 | 2021 | Michael Young Co-Founder & Co-CEO | WebflowApple iCloud MailGoogle Workspace+28 | 3 signals Leadership | — | — |
| 20 | Biofortuna Provider of manufacturing services for immunoassays, molecular diagnostics, and regulatory services | $22M | 3 mo ago | 32 32 → 31 (-3%) · sector median +45% | 2008 | Katherine Douglas Co-Founder | WordPressMySQLPHP+28 | — | 9 patents Molecular diagnostic reagents and kits for PCR amplification and tissue‑typing assays | — |
| 21 | Open Orphan Provider of testing vaccines & antivirals and CRO pharmaceutical services | $22M | 72 mo ago | 218 218 → 235 (+8%) · sector median +45% | 2017 | — | — | — | — | 1 award |
| 22 | TMC Provider of contract research and consulting services | $21M | 45 mo ago | 30 30 → 61 (+103%) · sector median +45% | 2001 | — | WordPressMySQLPHP+25 | — | — | 1 job opening · 1 partnership |
| 23 | Seda Provider of consulting services to biopharma sector | $20M | 3 mo ago | — | 2015 | Paul Dickinson Founder and CSO | WordPressPleskMySQL+21 | — | — | 2 job openings · 1 award |
| 24 | Mytos Provider of automated cell manufacturing for regenerative medicine applications | $19M | 32 mo ago | 19 | 2016 | Ignacio Willats Co-Founder | WebflowYouTubeHubSpot+11 | — | — | — |
| 25 | Discovery Biomed Contract research organization | $19M | 73 mo ago | 7 | 2007 | — | — | — | — | — |
| 26 | Cyprotex Predictive toxicology and in vitro and in silico ADME services provider | $17M | 89 mo ago | 17 | 1999 | — | — | — | — | 1 partnership |
| 27 | Trisk Provider of drug research & development services for pharmaceutical industry | $17M | 53 mo ago | 2 | 2020 | Gergo Bohner Co-Founder | — | — | — | 1 partnership |
| 28 | Panthera Clinical trials organization providing site management and patient recruitment services to pharmaceutical and… | $16M | 10 mo ago | 66 | 2019 | John Lyon Co-Founder & Chairman | — | — | 4 patents Provides modular support blocks for temporary construction hoarding systems | 1 award |
| 29 | Prescient Healthcare Group Consulting services for product strategy and decision support | $13M | 24 mo ago | 217 | 2007 | Jamie Denison Pender CEO | WordPressApple iCloud MailMicrosoft 365+31 | — | — | 1 launch · 1 award |
| 30 | Liverpool ChiroChem Small organic molecule supplier for biotech/pharmaceutical R&D | $11M | 43 mo ago | 14 | 2014 | — | — | — | — | — |
| 31 | Metrion Biosciences CRO specializing in ion channel screening, cardiac safety profiling and drug discovery services | $8M | 29 mo ago | 48 | 2015 | — | WordPressPleskMySQL+22 | — | 13 patents Design and synthesis of heterocyclic sulfonamide small‑molecule therapeutics | 1 job opening · 1 expansion |
| 32 | BDD pharma Provider of formulation development services specializing in gamma scintigraphy | $7M | 34 mo ago | 22 22 → 55 (+150%) · sector median +45% | 2010 | — | WordPressMySQLPHP+16 | — | — | 1 job opening |
| 33 | AWAKN CRO focused on early stage clinical trial research | $6M | 15 mo ago | 3 | 2020 | — | WordPressMySQLPHP+30 | — | — | — |
| 34 | CatSci Provider of drug discovery services | $6M | 48 mo ago | 63 63 → 99 (+57%) · sector median +45% | 2010 | — | WordPressMySQLPHP+25 | — | — | 1 award |
| 35 | Nexus BioQuest Provider of drug discovery services | $5M | 46 mo ago | 16 | 2022 | — | WordPress Block EditorWordPressMySQL+20 | — | — | 1 job opening |
| 36 | Life Science People Provider of drug discovery, regulatory, marketing, staffing, and other services for biopharma sector | $5M | 34 mo ago | 17 | 2020 | — | — | — | — | — |
| 37 | Glen Clova Scientific Developer of biologic drugs for chronic inflammatory conditions | $5M | 25 mo ago | — | 2022 | John Foerster Founder | BreakdanceWordPressMySQL+17 | — | — | — |
| 38 | SPARTA Biodiscovery Enabling nanoformulations for next-generation therapeutics through cutting-edge benchtop technology. | $4M | 32 mo ago | — | 2022 | Jelle Penders Chief Executive Officer | WordPressPleskMySQL+26 | — | — | 1 launch |
| 39 | ConcR Provider of a platform predicting therapeutic response and outcome for cancer | $3M | 33 mo ago | 6 | 2018 | Matt Foster CEO | Craft CMSPHPYii+11 | — | — | 1 partnership |
| 40 | Forge Genetics CRO focused on bioinformatics services | $3M | 8 mo ago | — | 2023 | Nigel Minton Co-Founder | WixSentryBootstrap+12 | — | 7 patents Design and production of synthetic nucleic acid therapeutics and gene‑editing constructs | 1 job opening |
| 41 | Exactmer CDMO focused on manufacturing of APIs | $3M | 39 mo ago | 24 24 → 22 (-8%) · sector median +45% | 2018 | Piers Gaffney Co-Founder | — | — | 15 patents Patents concentrated in chemistry & materials | — |
| 42 | Fusion Antibodies Company offering a range of services in antibody production, development, characterization and optimization… | $2M | 28 mo ago | 58 58 → 30 (-48%) · sector median +45% | 2001 | Adrian Kinkaid CEO | WordPressMySQLPHP+27 | — | 92 patents Therapeutic antibody discovery and engineering platforms for targeted biologic drugs | 3 launchs |
| 43 | NCIMB Provider of biorepository, microbial culture collection and microbiology services | $2M | 13 mo ago | 25 | 1982 | — | WordPressMySQLPHP+8 | — | 2 patents Enzymatic synthesis of cyclodextrins using cyclodextrin glucanotransferase | — |
| 44 | ImmuONE CRO focused on innovative solutions for inhalation safety | $2M | 15 mo ago | 8 | 2019 | Abigail Martin Co-Founder & CEO | — | — | — | — |
| 45 | GT LifeScience Provider of data science and engineering services to life sciences companies | $2M | 32 mo ago | — | 2020 | Andy Baynes Co-Founder & CEO | — | — | — | — |
| 46 | DeepMirror Provider of drug research & development, data analysis, and imaging services | $2M | 22 mo ago | 9 | 2019 | Ryan Greenhalgh Co-Founder and CTO | WebflowGSAPPlausible+18 | — | — | 1 launch · 1 partnership |
| 47 | Verisian Developer of clinical trial analysis solutions using traceability and AI | $1M | 33 mo ago | — | 2023 | Henning Kuich Co-Founder and CTO | WebflowHubSpotcore-js+14 | — | — | — |
| 48 | PBR Life Sciences Provider of market research consulting services for life science sector | $1M | 17 mo ago | — | 2015 | Oluyinka Yinka Co-Founder | WordPressMySQLZoho+24 | — | — | — |
| 49 | Magnitude Biosciences Provider of cell-free in vitro assay for drug discovery companies | $1M | 12 mo ago | 12 12 → 20 (+67%) · sector median +45% | 2018 | Fozia Saleem Chief Executive Officer | WordPress Block EditorOxygenWordPress+30 | — | 2 patents Automated imaging and analysis systems for nematode behavior tracking | 1 partnership |
| 50 | Myomaker Bio Provider of preclinical muscle biology solutions, including research, screening, and development | $429K | 3 mo ago | — | 2023 | Andrew Capel Co-Founder & Chief Scientific Officer | WordPressMySQLPHP+22 | — | — | — |
Top 12 Biopharma Outsourcing companies in United Kingdom
#1
Series A · Birkenhead, England · founded 2008 · 32 employees$21.6Mraised▾
Provider of manufacturing services for immunoassays, molecular diagnostics, and regulatory services
- Feb 2026Grant (prize money)$303.2K
- Mar 2021Series A—
- Aug 2018Series A$4.5M
- Jul 2017Series A$2.1M
#2
Series B · England · founded 2015$20Mraised▾
Provider of consulting services to biopharma sector
- Mar 2026Series B$20M
#3
Public · Oxford, England · founded 1995 · 815 employees$149.7Mraised▾
Manufacturer of viral vectors for cell and gene therapy products. Services include process development, analytical methods, and manufacturing support for advanced therapy developers. Expertise spans lentivirus, adeno-associated virus, and adenovirus platforms to facilitate the development and production of therapeutic treatments.
- Aug 2025Post IPO$81.3M
- Jan 2025Post IPO—
- Sep 2021Post IPO$68.3M
- Apr 2019Unattributed—
#4
Public · York, England · founded 2008 · 151 employees$24.1Mraised▾
Developer of immunoassays for diagnostic purposes. It offers a rapid lateral flow immunoassay system that enables multiplexed immunodiagnostics. Its flagship product Seralite- FLC measures kappa (K) and lambda (λ) immunoglobulin-free light chain used for the detection of hematological cancers. It als provide research services for a range of sectors including the clinical point of care, clinical self-test, pharmaceutical, and others.
- Oct 2025Post IPO$4.4M
- Jan 2019Series A$2.6M
- Dec 2017Series A$1.5M
- Jul 2016Series A$3.9M
#5
Late Stage · Preston, England · founded 2019 · 66 employees$15.9Mraised▾
Panthera Bio is a clinical trials organization that provides dedicated clinical trial sites in the UK, delivering clinical trials and patient recruitment services to pharmaceutical and contract research organizations. The company aims to transform the North Texas Biotechnology industry by offering efficient R&D and validation services, ensuring rapid development and accelerated timelines. With a focus on patient recruitment and site management, Panthera Bio supports the development of new medicines and treatments.
- Aug 2025PE—
- Jul 2019Grant (prize money)$2M
- Jun 2019Grant (prize money)$600K
- May 2019Grant (prize money)$5.3M
#6
Series B · London, England · founded 2021 · 7 employees$23Mraised▾
Provider of contract based clinical trial & recruitment services
- Jan 2025Series B$55M
- Aug 2023Series A$18M
- Jun 2023Seed—
- May 2023Grant (prize money)$543.1K
#7
Seed · Nottingham, England · founded 2023$3Mraised▾
CRO focused on bioinformatics services. It helps clients maintain their intellectual property while enabling high-precision gene knockouts and insertions. The company operates primarily as a contract research organization offering strain development services and aims to expand its technology into cell and gene therapy applications.
- Oct 2025Seed$2.7M
- Mar 2025Angel$305.5K
#8
Seed · Loughborough, Leicestershire · founded 2023$429.4Kraised▾
Provider of preclinical muscle biology solutions, including research, screening, and development. The company offers bespoke models of disease and injury. They deliver comprehensive assessment of muscle morphology and function across disease, exercise, injury, and rehabilitation. Standard outputs include muscle function, muscle morphology, gene and protein expression, and media analysis.
- Mar 2026Seed$429.4K
#9
Acquired · Portishead, England · founded 2020 · 3 employees$5.9Mraised▾
CRO focused on early stage clinical trial research
- Mar 2025Post IPO$141K
- Apr 2024Post IPO$95.9K
- Apr 2023Post IPO$575K
- Sep 2022Post IPO$1.9M
#10
Early Stage · United Kingdom · founded 1982 · 25 employees$2.5Mraised▾
Provider of biorepository, microbial culture collection and microbiology services. It offers microbiology, chemical analysis and biomaterial storage services to clients from the pharmaceutical, personal care, oil and gas, food, agriculture and environment industries, as well as from academia. The services include microbial identification, patent deposits, biomaterial storage, freeze drying, oilfield microbiology, toxicity testing, analytical services, and R&D support.
- Apr 2025Unattributed$2.3M
- Dec 2020Grant (prize money)$183K
- 2008Unattributed—
#11
Series D · Craigavon, Northern Ireland · founded 2001 · 2109 employees$338.8Mraised▾
Almac is a contract development and manufacturing organisation that provides a range of integrated services to biopharma companies. The services range from R&D, biomarker discovery and development, API manufacture, formulation development, clinical trial supply, companion diagnostics development, analytical services, commercial manufacturing services and clinical technologies. The company has facilities in Europe, North America and Asia.
- Sep 2022Grant (prize money)$416.7K
- Jan 2021Grant (prize money)$2.7M
- May 2020Grant (prize money)$288K
- Apr 2020Grant (prize money)$332.1K
#12
Seed · Durham, England · founded 2018 · 12 employees$1Mraised▾
Provider of cell-free in vitro assay for drug discovery companies. The services include pre screening of compounds, screening libraries of mutants, and screening compound libraries. It provides quantified non-invasive assays for health outcomes and drug discovery to biotech, nutrition, pharmaceutical, and academic sectors. Its services focus on areas such as aging, neurodegeneration, microbiome, toxicity, reproductive health, and disease modeling, using proprietary technology.
- May 2025Grant (prize money)—
- Mar 2025Seed$943.6K
- Oct 2022Seed$646.8K
- Aug 2020Seed$329.7K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Biopharma Outsourcing coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in the United Kingdom
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,508 United Kingdom-affiliated papers.
- Imperial College London70
- University College London67
- University of Cambridge54
- University of Edinburgh54
- University of Oxford48
- Gene4→31
- Population1→15
- Mutation1→13
- Chromatin1→11
- Mutant2→12
- Gene2→35
- Antimicrobial1→22
- Bacteria1→17
- Downregulation and upregulation1→17
- Antibody3→19
- Production (economics)3→14
- Antimicrobial4→14
- Agriculture9→18
- Sustainability1→10
- Food safety2→11
Where biotechnology is researched across United Kingdom
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing biotechnology patents in the United Kingdom
United Kingdom biotechnology patent filing is accelerating — 35,956 filings from 8,000 assignees (2016–2025), led by Medimmune, Glaxo Group, UCL Business; annual filings 2688→3463.
- Medimmune2939
- Glaxo Group1583
- UCL Business1576
- UNIV Oxford Innovation1145
- Glaxosmithkline IP DEV997
- Medical RES Council948
- Cambridge Entpr859
- Kymab850
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.